Skip to main content
Top
Published in: Journal of Cancer Survivorship 3/2018

01-06-2018

The continuum of breast cancer care and outcomes in the U.S. Military Health System: an analysis by benefit type and care source

Authors: Yvonne L. Eaglehouse, Stephanie Shao, Wenyaw Chan, Derek Brown, Janna Manjelievskaia, Craig D. Shriver, Kangmin Zhu

Published in: Journal of Cancer Survivorship | Issue 3/2018

Login to get access

Abstract

Purpose

This study investigates transition rates between breast cancer diagnosis, recurrence, and death by insurance benefit type and care source in U.S. Military Health System (MHS).

Methods

The MHS data repository and central cancer registry linked data were used to identify women aged 40–64 with histologically confirmed breast cancer between 2003 and 2007. Three-state continuous time Markov models were used to estimate transition rates and transition rate ratios (TRRs) by TRICARE benefit type (Prime or non-Prime) and care source (direct, purchased, or both), adjusted for demographic, tumor, and treatment variables.

Results

Analyses included 2668 women with transitions from diagnosis to recurrence (n = 832), recurrence to death (n = 79), and diagnosis to death without recurrence (n = 91). Compared to women with Prime within each care source, women with non-Prime using both care sources had higher transition rates (TRR 1.47, 95% CI 1.03, 2.10). Compared to those using direct care within each benefit type, women utilizing both care sources with non-Prime had higher transition rates (TRR 1.86, 95% CI 1.11, 3.13), while women with Prime utilizing purchased care had lower transition rates (TRR 0.82, 95% CI 0.68, 0.98).

Conclusions

In the MHS, women with non-Prime benefit plans compared to Prime had higher transition rates along the breast cancer continuum among both care source users. Purchased care users had lower transition rates than direct care users among Prime beneficiaries.

Implications for Cancer Survivors

Benefit plan and care source may be associated with breast cancer progression. Further research is needed to demonstrate differences in survivorship.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hassett MJ, Neville BA, Weeks JC. The relationship between quality, spending and outcomes among women with breast cancer. J Natl Cancer Inst. 2014;106(10). Hassett MJ, Neville BA, Weeks JC. The relationship between quality, spending and outcomes among women with breast cancer. J Natl Cancer Inst. 2014;106(10).
2.
go back to reference Boero IJ, Paravati AJ, Triplett DP, Hwang L, Matsuno RK, Mell LK, et al. The impact of radiotherapy costs on clinical outcomes in breast cancer. Radiother Oncol. 2015;117(2):393–9. Boero IJ, Paravati AJ, Triplett DP, Hwang L, Matsuno RK, Mell LK, et al. The impact of radiotherapy costs on clinical outcomes in breast cancer. Radiother Oncol. 2015;117(2):393–9.
8.
go back to reference Lee-Feldstein A, Feldstein PJ, Buchmueller T, Katterhagen G. The relationship of HMOs, health insurance, and delivery systems to breast cancer outcomes. Med Care. 2000;38(7):705–18.CrossRefPubMed Lee-Feldstein A, Feldstein PJ, Buchmueller T, Katterhagen G. The relationship of HMOs, health insurance, and delivery systems to breast cancer outcomes. Med Care. 2000;38(7):705–18.CrossRefPubMed
11.
go back to reference Chen TH, Kuo HS, Yen MF, Lai MS, Tabar L, Duffy SW. Estimation of sojourn time in chronic disease screening without data on interval cases. Biometrics. 2000;56(1):167–72.CrossRefPubMed Chen TH, Kuo HS, Yen MF, Lai MS, Tabar L, Duffy SW. Estimation of sojourn time in chronic disease screening without data on interval cases. Biometrics. 2000;56(1):167–72.CrossRefPubMed
12.
go back to reference Li YP, Chan W. Analysis of longitudinal multinomial outcome data. Biometrical journal Biometrische Zeitschrift. 2006;48(2):319–26. Li YP, Chan W. Analysis of longitudinal multinomial outcome data. Biometrical journal Biometrische Zeitschrift. 2006;48(2):319–26.
16.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRefPubMed
17.
go back to reference American Joint Committee on Cancer. Breast. In: Eds. F.L. Greene, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG et al., editors. AJCC Cancer Staging Manual. Sixth Edition ed. United States of America: Springer; 2002. p. 223–40. American Joint Committee on Cancer. Breast. In: Eds. F.L. Greene, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG et al., editors. AJCC Cancer Staging Manual. Sixth Edition ed. United States of America: Springer; 2002. p. 223–40.
18.
go back to reference Stokes ME, Thompson D, Montoya EL, Weinstein MC, Winer EP, Earle CC. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. Value in health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research. 2008;11(2):213–20.CrossRef Stokes ME, Thompson D, Montoya EL, Weinstein MC, Winer EP, Earle CC. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. Value in health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research. 2008;11(2):213–20.CrossRef
30.
go back to reference National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. 2017. www.nccn.org. Accessed: 6 April 2017. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. 2017. www.​nccn.​org. Accessed: 6 April 2017.
Metadata
Title
The continuum of breast cancer care and outcomes in the U.S. Military Health System: an analysis by benefit type and care source
Authors
Yvonne L. Eaglehouse
Stephanie Shao
Wenyaw Chan
Derek Brown
Janna Manjelievskaia
Craig D. Shriver
Kangmin Zhu
Publication date
01-06-2018
Publisher
Springer US
Published in
Journal of Cancer Survivorship / Issue 3/2018
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-018-0680-1

Other articles of this Issue 3/2018

Journal of Cancer Survivorship 3/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine